# CorMedix Inc. (CRMD)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $725,582.78  
**Price:** $9.04 (+3.02%)

> CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, particularly in anti-infective therapies and hospital-based treatments in the United States. Its lead product, DefenCath, is an FDA-approved antimicrobial catheter lock solution containing taurolidine and heparin, designed to reduce catheter-related bloodstream infections in adult patients with kidney failure undergoing chronic hemodialysis via central venous catheters. This product serves outpatient dialysis organizations and holds a unique position as the first such approved solution in its indication. Following the acquisition of Melinta Therapeutics in August 2025, CorMedix Inc. expanded its commercial portfolio to include seven innovative anti-infective drugs: MINOCIN for injection, REZZAYO for candidemia and invasive candidiasis, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. These therapies strengthen its presence in acute care settings, infectious disease management, and hospital markets, diversifying beyond dialysis applications. Incorporated in 2006 and headquartered in Berkeley Heights, New Jersey, CorMedix Inc. operates as a single drug product segment emphasizing commercial sales and strategic investments in specialty pharmaceuticals.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $312M | $276M | $150M | $163M | — |
| 2024 | $43M | $40M | -$22M | -$18M | — |
| 2022 | $65,408 | $61,674 | -$31M | -$30M | — |
| 2021 | $190,936 | $41,998 | -$29M | -$28M | — |
| 2020 | $239,231 | $34,385 | -$27M | -$22M | — |
| 2019 | $283,266 | -$89,968 | -$21M | -$16M | — |
| 2018 | $429,797 | $33,011 | -$27M | -$27M | — |
| 2017 | $329,327 | $214,363 | -$33M | -$33M | — |
| 2016 | $224,105 | -$142,568 | -$25M | -$25M | — |
| 2015 | $210,130 | -$108,588 | -$17M | -$18M | — |
| 2014 | $189,274 | -$256,525 | -$9M | -$20M | — |
| 2013 | $2,001 | -$199,604 | -$5M | -$9M | — |
| 2012 | — | — | -$3M | -$3M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $826M | $421M | $405M | $145M | — |
| 2024 | $119M | $34M | $85M | $41M | — |
| 2022 | $62M | $7M | $55M | $43M | — |
| 2021 | $69M | $6M | $63M | $53M | — |
| 2020 | $49M | $5M | $44M | $42M | — |
| 2019 | $29M | $6M | $24M | $16M | — |
| 2018 | $19M | $14M | $5M | $18M | — |
| 2017 | $13M | $6M | $7M | $10M | — |
| 2016 | $22M | $4M | $18M | $8M | — |
| 2015 | $37M | $3M | $34M | $12M | — |
| 2014 | $5M | $1M | $4M | $4M | — |
| 2013 | $3M | $7M | -$4M | $2M | — |
| 2012 | $1M | $1M | -$335,376 | $835,471 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $175M | $2M | $173M |
| 2024 | -$51M | $116,000 | -$51M |
| 2023 | -$38M | $327,300 | -$39M |
| 2022 | -$24M | $219,360 | -$25M |
| 2021 | -$21M | $1M | -$23M |
| 2020 | -$22M | $112,638 | -$22M |
| 2019 | -$15M | $36,571 | -$15M |
| 2018 | -$24M | $48,893 | -$24M |
| 2017 | -$29M | $151,988 | -$29M |
| 2016 | -$22M | $58,723 | -$22M |
| 2015 | -$13M | $15,446 | -$13M |
| 2014 | -$6M | $25,402 | -$6M |
| 2013 | -$4M | $35,683 | -$4M |
| 2012 | -$2M | — | -$2M |
| 2011 | -$6M | $1,625 | -$6M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CRMD)